- Home
- NEWS
- REGIONAL
- THIS WEEK'S PAPER
- BLOGS
- Multimedia
- OPINION
- A&E
- LISTS
- PEOPLE
- EVENTS
- Classifieds
- Subscribe
Pharmaceutical
Lilly wins approval of antidepressant Cymbalta for pain
November 4, 2010
Bloomberg NewsThe Food and Drug Administration has cleared Cymbalta for musculoskeletal pain such as arthritis and chronic lower back conditions,
which could mean another $500 million in annual sales for Lilly, an analyst estimates.
MoreAppeals court rejects Lilly over Gemzar patent
November 1, 2010
IBJ Staff and Bloomberg NewsWithout an appeal, generic drugs are now poised to wipe away most of Lilly's $750 million in annual U.S. revenue from Gemzar.
MoreIndiana's life sciences industry sees trouble ahead
October 30, 2010
Associated PressIndiana's life sciences industry has weathered the recession relatively well, but Eli Lilly's struggles and tight capital
markets could threaten the future.
MoreAnalysts: Lilly setbacks might spur shopping spree
October 22, 2010
Bloomberg NewsCEO John Lechleiter claims Eli Lilly and Co. isn't interested in big acquisitions to bolster its flagging drug pipeline, but
its recently devalued partner Amylin Pharmaceuticals might be the right fit, industry analysts say.
MoreAnalysts grill Lilly execs on strategy after setbacks
October 21, 2010
J.K. WallWall Street analysts on Thursday demanded to know what new things Eli Lilly and Co. is planning since the company’s vaunted
pipeline has failed to produce a drug that will boost revenue after a wave of patent expirations. The answer: Not much.
MoreLilly raises forecast after beating third-quarter profit estimates
October 21, 2010
J.K. WallThe Indianapolis-based drugmaker reported a profit of $1.3 billion in the quarter ended Sept. 30, up 38 percent compared with
last year. Excluding extraordinary items from a year ago, Lilly’s profit was up 2 percent.
MoreLilly suspends clinical trials after diabetes treatment fails
October 20, 2010
Bloomberg NewsEli Lilly and Co. and its development partner said an experimental diabetes treatment failed to help patients in a late-stage
study, the second setback for a Lilly diabetes drug candidate in two days.
MoreUPDATE: Lilly, others see stock slide after drug rejection
October 20, 2010
Bloomberg NewsStock in Eli Lilly and Co., Amylin Pharmaceuticals Inc. and Alkermes Inc. dropped after they were rebuffed a second time in
a bid to gain U.S. approval of a once-weekly version of the diabetes drug Byetta.
MoreFDA demands more tests on new Lilly diabetes drug
October 19, 2010
J.K. WallEli Lilly and Co. will have to wait at least 18 months and conduct more studies before it wins market approval of a once-weekly
version of diabetes drug Byetta, a potential billion-dollar drug.
MoreLilly to close drug discovery center in Singapore
October 18, 2010
Bloomberg NewsIndianapolis-based Eli Lilly and Co. will close its drug discovery center in Singapore, three years into a five-year, $150
million plan to expand it.
MoreLilly falls short on 'field goal' attempt
October 13, 2010
J.K. WallEli Lilly and Co.’s “miss” on a new use for its cancer drug Alimta was a rare failure to get an existing
drug approved for a new use—even though the company has struggled mightily to get entirely new drugs to market.
MoreLilly's Erbitux shows mixed results in cancer studies
October 11, 2010
Bloomberg NewsIn combination with chemotherapy, the drug failed to help colon-cancer patients in a European trial but did delay the spread
of breast cancer in some patients with a certain type of aggressive tumor.
MoreConsultants: Pharma industry facing huge changes
October 6, 2010
J.K. Wall
To date, most analysts say health reform turned out pretty well for
the pharmaceutical industry. But a detailed analysis by Deloitte Consulting says the indirect effects of reform will deliver
a gut punch to the industry that will lead to full-scale transformation akin to what the telecommunications world has seen
over the past three decades.
Drugmakers’ ‘doughnut hole’ deal to shave sales
October 1, 2010
Bloomberg NewsDrugmakers including Pfizer Inc., AstraZeneca, Bristol-Myers Squibb Co. and Eli Lilly and Co. may provide more than $2 billion
in drug discounts to senior citizens next year under a deal pharmaceutical companies made with the White House.
MoreLilly sues drug distributor over generic Zyprexa sales
September 29, 2010
Bloomberg NewsCelesio's Lloyds Pharmacy and Aah Pharmaceuticals businesses sold about 800,000 tablets of generic Zyprexa before agreeing
in 2008 to halt sales, Lilly said in a complaint filed in the High Court in London.
MoreLilly discovers social media
September 22, 2010
J.K. WallEli Lilly and Co. launched its own blog this month, dubbed LillyPad, to try to start discussions about public policy and corporate
social responsibility. The Indianapolis-based drugmaker also launched an accompanying Twitter feed.
MoreLilly wins reversal of class action in Zyprexa suit
September 10, 2010
Bloomberg NewsA U.S. appeals court in New York threw out a September 2008 ruling that said plaintiffs could pursue as a group claims that
Zyprexa marketing caused them to pay more for the drug than what it was worth. The plaintiffs were seeking $6.8 billion in
damages.
MoreIndiana to get share of Botox settlement
September 3, 2010
Associated PressBotox maker Allergan Inc. said it would pay $600 million to settle a years-long federal investigation into its marketing of
the drug. Indiana will get $636,000 of that money.
MoreAppeals court ruling upholds Lilly's Evista patents
September 1, 2010
Bloomberg NewsEli Lilly and Co. won a court ruling Wednesday that blocks plans by Teva Pharmaceutical Industries Ltd. to sell a generic
version of the Evista osteoporosis treatment before March 2014.
MoreLilly wins ban of generic Strattera pending appeal
August 31, 2010
Bloomberg NewsThe U.S. Court of Appeals for the Federal Circuit in Washington on Tuesday granted Lilly's request to prevent sales until
the court rules on a judge's decision invalidating a patent on the medicine.
MoreLilly wins further delay in sales of Strattera copies
August 26, 2010
Bloomberg NewsStrattera generated U.S. sales of $445.6 million last year, and each day that Lilly can fend off generic competition would
translate into an average $1.22 million in sales.
MoreDiabetes research pioneer Kirtley dies at 96
August 25, 2010
Associated PressDiabetics who control their disease with pills instead of frequent insulin injections can thank Dr. William R. Kirtley, a
groundbreaking Eli Lilly researcher.
MorePearl IRB first firm in state to pre-screen clinical drug trials
August 21, 2010
Chris O'MalleyTwo former Eli Lilly and Co. employees launched the firm that promises to attract more clinical trial business to the state.
MoreLilly gains panel's backing to expand Cymbalta use
August 19, 2010
Bloomberg NewsOutside advisers to the Food and Drug Administration voted 8-6 Thursday in favor of a broader use of Cymbalta on the basis
of studies in lower back pain and osteoarthritis of the knee.
MoreLilly wins temporary ban on sales of Strattera copies
August 19, 2010
Bloomberg NewsThe invalidation of Lilly's Strattera patent opened the door for as many as 10 companies to sell generic versions of the drug,
which generated U.S. sales of $445.6 million last year as a treatment for attention deficit hyperactivity disorder.
More
Sponsored by
ADVERTISEMENT
on Facebook & Twitter
on Facebook & Twitter
 Follow IBJ's Tweets on these topics: |
||
| @IBJNews | @Propertylines | @IBJTheScore |
| @IBJArts | @IBJHealthcare | @IBJDining |
| @IBJLists | @IBJSmallbiz | |
ADVERTISEMENT
Back to TopCopyright © All Rights Reserved. Privacy Policy | Terms of Use.
Design, CMS, Hosting & Web Development :: ePublishing.
Additional Hosting & Delivery by
Doug Henning!
These guy were thugs — they grew up in freaking Haughville! Smh, sigh. If the mayor needs/wants "quality" Black Hoosiers who are NOT corrupt, give me a call — I know plenty. Land bank info here - http://www.kubepharm.com/indylandbank/IndyLandBank.html
Magician and illusionist!
The basic idea of nice apartments with parking and retail is a good one, but this design seems overwhelmingly big/tall for Broad Ripple. The size could be disguised a bit with lots of big trees/landscaping, but the complex is too massive to blend in easily. That section of canal between College and Westfield will also need to be upgraded on both sides. Nice apartments facing onto a nice promenade with shade trees/plantings could bring together the canal towpath/Monon recreation, the outdoor seating at existing restaurants, and this project into something that upgrades the whole area. A plan for the whole stretch makes more sense than facing nice new housing onto what looks like a ditch. Is there a plan? Does the public have input? Who pays? The apartment idea seems to be reasonable, but Whole Foods is not a good idea for appropriate retail. Besides the store being physically too big, there are already Fresh Market at 54xCollege and Whole Foods in Nora for fancy groceries. Good Earth and Kroger are within walking distance of the Shell site. There are at least 7 grocery stores within a safe bike ride. Whole Foods would add nothing but traffic congestion. This design is on the right track, but there needs to be more work done to ensure that it blends in with and enhances the existing community. A project that large will set a tone for that whole part of town. It could be a real asset, but only if done right.
I did not move to Zionsville to live in Carmel. This and the subsequent developments to follow will ensure a vanilla uniformity of strip malls and apartment buildings as we seek to bring our town down to the least common denominator. We were warned before recent elections that pro-development council members would make sure their friends (landowners and developers) would be able to make their millions off of the exploitation of Zionsville. Why in God's name would we sell out the best preserved small town in the State of Indiana?